NEU 3.40% $14.30 neuren pharmaceuticals limited

Ann: 2023 Annual Report to shareholders, page-178

  1. 2,457 Posts.
    lightbulb Created with Sketch. 835
    Investing in OS companies presents challenges and disadvantages many don't want to bother with. It's a possible solution but for many not a user friendly one. Especially vs getting fair value up front.
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.